多利益相关方改良Delphi专家小组:新兴监测方案背景下HCC监测的价值
肝病专业学会推荐HCC监测,但现有数据局限性使其未获初级保健和癌症学会广泛接受。研究采用严格改良Delphi法召集多学科癌症筛查专家,评估HCC预防与早期检测的当前和未来模式。专家在21项关于一级预防、监测获益、监测危害及新兴监测方式评估的陈述上高度一致,认为监测总体价值高,尤其患者和临床医生更重视获益。
要点
- 专家在21项关于HCC监测获益、危害及新兴方式评估的陈述上高度一致。
- 现有数据存在方法学局限,对西方人群的普适性不明确。
- 随机对照试验不可行时,可比较两种监测方式提供间接疗效证据。
核心结论
- 专家小组认为HCC监测的总体价值似乎较高,尤其患者和临床医生更强调获益而非危害。
- 评估新兴监测策略时需建立同时测量获益与危害的框架。
研究设计与样本
- 采用严格改良Delphi专家小组方法,召集多学科癌症筛查专家。
- 专家小组评估HCC预防和早期检测的当前与未来模式,并对21项陈述达成高度一致。
主要发现
- 专家一致认为现有数据存在方法学局限,且对西方人群的普适性不明确。
- 专家认为随机对照试验比较监测与不监测不太可行,但比较两种监测方式的替代设计可提供间接疗效证据。
- 专家承认监测存在危害,但认为总体价值高,因患者和临床医生更重视获益。
- 专家强调评估新兴监测策略时需测量获益与危害的框架。
- 新兴方法的性能指标可能因人群癌症风险更高、竞争死亡风险及诊断流程差异而不同于其他癌症筛查项目。
临床怎么用
- 临床应认识HCC监测总体价值较高,同时关注监测危害。
- 评估新兴血基和影像监测策略时,需同时测量获益与危害。
局限性
- 现有数据存在方法学局限,对西方人群普适性不明确。
- 随机对照试验比较监测与不监测不太可行。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
HCC surveillance is recommended by liver professional societies but lacks broad acceptance by several primary care and cancer societies due to limitations in the existing data. We convened a diverse multidisciplinary group of cancer screening experts to evaluate current and future paradigms of HCC prevention and early detection using a rigorous Delphi panel approach. The experts had high agreement on 21 statements about primary prevention, HCC surveillance benefits, HCC surveillance harms, and the evaluation of emerging surveillance modalities. The experts agreed that current data have methodologic limitations as well as unclear generalizability to Western populations. Although a randomized clinical trial of surveillance versus no surveillance is unlikely feasible, they concurred that alternative designs, such as a comparison of 2 surveillance modalities, could provide indirect evidence of surveillance efficacy. The panel acknowledged the presence of surveillance harms, but concurred the overall value of surveillance appears high, particularly given a greater emphasis on benefits over harms by both patients and clinicians. The experts underscored the importance of a framework for measuring both benefits and harms when evaluating emerging surveillance strategies. The panel acknowledged performance metrics of emerging methods may differ from other cancer screening programs given differences in populations, including higher risk of cancer development and competing risk of morality, and differences in diagnostic workflow in patients at risk of HCC. These data provide insights into the perceived value of HCC surveillance in an era of emerging blood- and imaging-based surveillance strategies.
引用
- Singal AG, Quirk L, Boike J, et al. Value of HCC surveillance in a landscape of emerging surveillance options: Perspectives of a multi-stakeholder modified Delphi panel. Hepatology. 2024. PMID: 40833999. doi:10.1097/HEP.0000000000001203
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。